[HTML][HTML] JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
P Guglielmelli, GG Loscocco, C Mannarelli… - Blood cancer …, 2021 - nature.com
Arterial (AT) and venous (VT) thrombotic events are the most common complications in
patients with polycythemia vera (PV) and are the leading causes of morbidity and mortality …
patients with polycythemia vera (PV) and are the leading causes of morbidity and mortality …
2021 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: a review of current data and applications on risk stratification and management
H Ali, A Bacigalupo - American Journal of Hematology, 2021 - Wiley Online Library
The number of patients with myelofibrosis (MF) undergoing an allogeneic hemopoietic stem
cell transplantation (HSCT) is increasing: in the analysis of the European Group for Blood …
cell transplantation (HSCT) is increasing: in the analysis of the European Group for Blood …
Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives
GG Loscocco, AM Vannucchi - International Journal of Hematology, 2022 - Springer
Classic Philadelphia-negative myeloproliferative neoplasms (MPN) include polycythemia
vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), classified as primary …
vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), classified as primary …
Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis
Ruxolitinib is a recommended second-line treatment for the prevention of thrombosis in
patients with polycythemia vera who become resistant or intolerant to hydroxyurea; however …
patients with polycythemia vera who become resistant or intolerant to hydroxyurea; however …
[HTML][HTML] Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis
Pre-fibrotic myelofibrosis (pre-PMF) and essential thrombocythemia (ET) are characterized
by similarly increased rate of thrombotic events, but no study specifically analyzed risk …
by similarly increased rate of thrombotic events, but no study specifically analyzed risk …
[HTML][HTML] Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district …
V De Stefano, E Rossi, A Carobbio, A Ghirardi… - Blood cancer …, 2018 - nature.com
We collected 1500 patients with myeloproliferative neoplasms (MPN) and arterial or venous
thrombosis (935/565), pooling three independent cohorts previously reported. Long-term …
thrombosis (935/565), pooling three independent cohorts previously reported. Long-term …
Long‐term pharmacodynamic and clinical effects of twice‐versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial
Patients with essential thrombocythemia (ET) are treated with once‐daily low‐dose aspirin
to prevent thrombosis, but their accelerated platelet turnover shortens the antiplatelet effect …
to prevent thrombosis, but their accelerated platelet turnover shortens the antiplatelet effect …
[HTML][HTML] Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
F Cervantes, DM Ross, A Radinoff, F Palandri… - Leukemia, 2021 - nature.com
Anemia is a frequent manifestation of myelofibrosis (MF) and there is an unmet need for
effective treatments in anemic MF patients. The REALISE phase 2 study (NCT02966353) …
effective treatments in anemic MF patients. The REALISE phase 2 study (NCT02966353) …
[HTML][HTML] Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program
A Rambaldi, A Iurlo, AM Vannucchi, B Martino… - Blood cancer …, 2021 - nature.com
Polycythemia vera (PV) is a BCR-ABL1-negative myeloproliferative neoplasm (MPN)
characterized by excessive proliferation of erythroid, myeloid, and megakaryocytic …
characterized by excessive proliferation of erythroid, myeloid, and megakaryocytic …
Current management strategies for polycythemia vera and essential thrombocythemia
P Guglielmelli, AM Vannucchi - Blood Reviews, 2020 - Elsevier
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative
neoplasms characterized by increased rate of cardiovascular events, a varying burden of …
neoplasms characterized by increased rate of cardiovascular events, a varying burden of …